Nothing Special   »   [go: up one dir, main page]

CL2016003191A1 - Polipéptidos receptores formulados y métodos relacionados - Google Patents

Polipéptidos receptores formulados y métodos relacionados

Info

Publication number
CL2016003191A1
CL2016003191A1 CL2016003191A CL2016003191A CL2016003191A1 CL 2016003191 A1 CL2016003191 A1 CL 2016003191A1 CL 2016003191 A CL2016003191 A CL 2016003191A CL 2016003191 A CL2016003191 A CL 2016003191A CL 2016003191 A1 CL2016003191 A1 CL 2016003191A1
Authority
CL
Chile
Prior art keywords
formulated
related methods
receptor polypeptides
protein
composition
Prior art date
Application number
CL2016003191A
Other languages
English (en)
Inventor
Michael Haqq Christopher
Latypov Ramil
Original Assignee
Santa Maria Biotherapeutics Inc
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santa Maria Biotherapeutics Inc, Amgen Inc filed Critical Santa Maria Biotherapeutics Inc
Publication of CL2016003191A1 publication Critical patent/CL2016003191A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

<p>Composición que comprende una solución de proteína, donde la proteína se selecciona de un polipéptido capaz de unirse a miostatina, activina A o GDF-11; método de producción de la proteína; y uso de la composición para inhibir el crecimiento de un tumor sólido.</p>
CL2016003191A 2014-06-13 2016-12-13 Polipéptidos receptores formulados y métodos relacionados CL2016003191A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462012104P 2014-06-13 2014-06-13
US201462047995P 2014-09-09 2014-09-09
US201462058789P 2014-10-02 2014-10-02
US201562142812P 2015-04-03 2015-04-03

Publications (1)

Publication Number Publication Date
CL2016003191A1 true CL2016003191A1 (es) 2017-11-10

Family

ID=54834575

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016003191A CL2016003191A1 (es) 2014-06-13 2016-12-13 Polipéptidos receptores formulados y métodos relacionados

Country Status (19)

Country Link
US (2) US20170202909A1 (es)
EP (1) EP3155008B1 (es)
JP (1) JP2017519009A (es)
KR (1) KR20170035891A (es)
CN (1) CN107074931A (es)
AP (1) AP2016009647A0 (es)
AU (1) AU2015274293A1 (es)
BR (1) BR112016029211A2 (es)
CA (1) CA2952231A1 (es)
CL (1) CL2016003191A1 (es)
EA (1) EA201692568A1 (es)
IL (1) IL249373A0 (es)
MX (1) MX2016016281A (es)
PE (1) PE20170471A1 (es)
PH (1) PH12016502479A1 (es)
SG (1) SG11201610432UA (es)
TN (1) TN2016000551A1 (es)
TW (1) TW201625675A (es)
WO (1) WO2015192127A2 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
CN103479994B (zh) 2005-11-23 2019-08-30 阿塞勒隆制药公司 Activin-ActRIIa拮抗剂及其促进骨骼生长的应用
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
MX2009008222A (es) 2007-02-01 2009-10-12 Acceleron Pharma Inc Antagonistas de activina-actriia y usos para tratar o prevenir cancer de mama.
TWI782836B (zh) 2007-02-02 2022-11-01 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
TWI667038B (zh) 2007-02-09 2019-08-01 美商艾瑟勒朗法瑪公司 包含ＡｃｔＲＩＩａ-Ｆｃ融合蛋白的醫藥組合物；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防與癌症相關的骨質流失之用途；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防多發性骨髓瘤之用途
CN103877564A (zh) 2007-09-18 2014-06-25 阿塞勒隆制药公司 活化素-actriia拮抗剂和减少或抑制fsh分泌的用途
WO2010019261A1 (en) 2008-08-14 2010-02-18 Acceleron Pharma Inc. Use of gdf traps to increase red blood cell levels
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
AU2010258931B2 (en) 2009-06-08 2015-04-23 Acceleron Pharma Inc. Methods for increasing thermogenic adipocytes
CN102656187A (zh) 2009-06-12 2012-09-05 阿塞勒隆制药公司 截短的actriib-fc融合蛋白
EP2501400B1 (en) 2009-11-17 2017-11-01 Acceleron Pharma, Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
WO2014121221A1 (en) 2013-02-01 2014-08-07 Santa Maria Biotherapeutics, Inc. Administration of an anti-activin-a compound to a subject
KR20130132824A (ko) 2010-11-08 2013-12-05 악셀레론 파마 인코포레이티드 Actriia 결합제 및 이의 용도
CA2890217C (en) 2012-11-02 2021-07-20 Yifu FANG Activin-actrii antagonists and uses for treating bone and other disorders
AP2017009674A0 (en) 2014-06-13 2017-01-31 Acceleron Pharma Inc Methods and compositions for treating ulcers
PL3286206T3 (pl) 2015-04-22 2021-09-13 Biogen Ma Inc. Nowe hybrydowe białka pułapki na ligand actriib do leczenia chorób powodujących zanik mięśni
EP3538128A4 (en) 2016-11-10 2020-07-22 Keros Therapeutics, Inc. ACTIVIN TYPE IIA RECEPTOR VARIANTS AND THEIR METHODS OF USE
US11932699B2 (en) 2017-09-07 2024-03-19 Jcr Pharmaceuticals Co., Ltd. Aqueous pharmaceutical composition
JP7258021B2 (ja) 2017-11-09 2023-04-14 ケロス セラピューティクス インコーポレイテッド アクチビンＩＩａ型受容体変異体を含む医薬組成物
KR20200109330A (ko) 2018-01-12 2020-09-22 케로스 테라퓨틱스, 인크. 액티빈 수용체 유형 iib 변이체 및 그의 사용 방법
KR20210091120A (ko) * 2018-08-29 2021-07-21 트랜슬레이트 바이오 인코포레이티드 Mrna-로딩된 지질 나노입자를 제조하는 개선된 공정
CA3112060A1 (en) * 2018-10-12 2020-04-16 Advanced Accelerator Applications International Sa Pharmaceutical composition comprising a radiolabeled gprp antagonist and a surfactant

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
WO1990014363A1 (en) 1989-05-19 1990-11-29 Amgen Inc. Metalloproteinase inhibitor
PT1129190E (pt) 1998-11-13 2007-08-08 Immunex Corp Adn e polipéptidos de tslp humanos.
JP4038118B2 (ja) 2002-11-29 2008-01-23 株式会社コガネイ 流体圧シリンダ
US9283260B2 (en) * 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
TWI454479B (zh) * 2007-03-06 2014-10-01 Amgen Inc 變異之活動素受體多肽及其用途
SG2013054218A (en) * 2008-01-15 2014-10-30 Abbott Gmbh & Co Kg Powdered protein compositions and methods of making same
RS55369B1 (sr) * 2008-11-26 2017-03-31 Amgen Inc Stabilizovana varijanta aktivin iib receptora
WO2014121221A1 (en) * 2013-02-01 2014-08-07 Santa Maria Biotherapeutics, Inc. Administration of an anti-activin-a compound to a subject
EP2568960B1 (en) * 2010-05-10 2018-06-06 Intas Pharmaceuticals Ltd. Liquid formulation of polypeptides containing an fc domain of an immunoglobulin
US9401875B2 (en) 2012-06-01 2016-07-26 Nippon Telegraph And Telephone Corporation Packet transfer processing method and packet transfer processing device
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof
WO2016205370A1 (en) * 2015-06-15 2016-12-22 Santa Maria Biotherapeutics, Inc. Methods of using activin receptor iib-based proteins

Also Published As

Publication number Publication date
TW201625675A (zh) 2016-07-16
CN107074931A (zh) 2017-08-18
WO2015192127A3 (en) 2016-03-17
PH12016502479A1 (en) 2017-04-10
EP3155008B1 (en) 2020-08-26
AP2016009647A0 (en) 2016-12-31
KR20170035891A (ko) 2017-03-31
CA2952231A1 (en) 2015-12-17
JP2017519009A (ja) 2017-07-13
PE20170471A1 (es) 2017-05-14
AU2015274293A1 (en) 2017-02-02
IL249373A0 (en) 2017-02-28
EA201692568A1 (ru) 2017-05-31
EP3155008A2 (en) 2017-04-19
EP3155008A4 (en) 2018-05-16
SG11201610432UA (en) 2017-01-27
TN2016000551A1 (en) 2018-04-04
WO2015192127A2 (en) 2015-12-17
MX2016016281A (es) 2017-03-31
US20170202909A1 (en) 2017-07-20
US20240277805A1 (en) 2024-08-22
BR112016029211A2 (pt) 2018-01-30

Similar Documents

Publication Publication Date Title
CL2016003191A1 (es) Polipéptidos receptores formulados y métodos relacionados
CL2017001566A1 (es) Derivados de azabiciclootano como agonistas de fxr para el uso en el tratamiento de enfermedades hepáticas y gastrointestinales.
CL2017002422A1 (es) Derivados de maitansinoide, conjugados de los mismos, y métodos de uso.
CL2017001289A1 (es) Compuestos bicíclicos fusionados, sus composiciones y su uso para el tratamiento de enfermedades relacionadas con la modulación del receptor x farnesoide (fxr).
EA201791117A1 (ru) Частичные агонисты инсулинового рецептора
DK3121175T3 (da) 1,3-benzodioxolderivater som ezh1- og/eller ezh2-hæmmere
CL2016002735A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
EA201890493A1 (ru) РЕПРЕССОРЫ Htt И ИХ ПРИМЕНЕНИЕ
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
EA201691991A1 (ru) Мультиспецифические антитела
AR101905A1 (es) Compuestos bicíclicos
EA201692425A1 (ru) Модифицированные биополимеры и способы их получения и использования
CR20160362A (es) Anticuerpos anti-jagged1 y metodos de uso
BR112017013568A2 (pt) compostos bicíclicos fundidos para o tratamento de doenças
CL2017000506A1 (es) Nuevos anticuerpos anti-mfi2 y metodos de uso
DOP2017000112A (es) Síntesis de copanlisib y su sal diclorhidrato
EA201691363A1 (ru) Стабилизированные силикатные композиции и их применение в качестве антиперспирантных композиций
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
UY36396A (es) Síntesis de copanlisib y su sal diclorhidrato
CL2017000151A1 (es) Derivados de piridona
BR112016029510A2 (pt) métodos para a preparação de um composto, e, composto intermediário.
CL2020001753A1 (es) Composiciones y metodos para la liberación de ciclopropenos.
BR112016018371A2 (pt) derivado de indolona substituído com pirrol, método de preparação do mesmo, composição compreendendo o mesmo e uso do mesmo
BR112016027455A2 (pt) moduladores ppar